MetLife Investment Management, LLC - 14 Dec 2020 Form 4 Insider Report for Neuberger Berman High Yield Strategies Fund Inc. (NHS)

Role: 10%+ Owner
Signature: /s/ Israel Grafstein, Chief Compliance Officer of MetLife Investment Management, LLC
Issuer symbol: NHS
Transactions as of: 14 Dec 2020
Net transactions value: -$53,002,712,952,189
Form type: 4
Filing time: 10 Jun 2022, 16:45:51 UTC
Previous filing: 10 Jun 2022
Next filing: 26 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NHS	Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023	Other	$7,833,084,604,780	-2,794,633	-35%	$2802902.78^*	5,190,034	14 Dec 2020	See Footnotes	F1, F3, F4, F5
transaction	NHS	Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023	Other	$9,537,549,142,359	-3,083,733	-35%	$3092858.28^*	5,726,934	14 Dec 2020	See Footnotes	F1, F3, F4, F5
transaction	NHS	Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023	Other	$21,422,707,174,650	-4,621,634	-35%	$4635310.19^*	8,583,032	14 Dec 2020	See Footnotes	F1, F3, F4, F5
transaction	NHS	Series C Mandatory Redeemable Preferred Shares	Other	$12,332,541,450,560	-992,000	-20%	$12431997.43^*	3,968,000	14 Dec 2020	See Footnotes	F2, F3, F4, F5
transaction	NHS	Series C Mandatory Redeemable Preferred Shares	Other	$461,989,065,600	-192,000	-20%	$2406193.05^*	768,000	14 Dec 2020	See Footnotes	F2, F3, F4, F5
transaction	NHS	Series C Mandatory Redeemable Preferred Shares	Other	$1,414,841,514,240	-336,000	-20%	$4210837.84^*	1,344,000	14 Dec 2020	See Footnotes	F2, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These Floating Rate Senior Notes, Series A Notes, due September 18, 2023 ("Notes") were redeemed, in part, by the Issuer pursuant to a partial prepayment of the principal plus accrued and unpaid interest.
F2	These Series C Mandatory Redeemable Preferred Shares ("Series C MRPS") were redeemed, in part, by the Issuer at a price equal to the liquidation preference of $12.50 per share plus accumulated and unpaid dividends.
F3	This price reflects the aggregate amount received in exchange for the redemption.
F4	These Notes and Series C MRPS are held directly by clients for whom the Reporting Person serves as investment manager.
F5	The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.